This is a 6 months, active treatment, extension study, open to subjects who have completed
full 24 weeks in Study MBGS205 (A Phase IIb multicentre, double-blind, dose-ranging,
randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese
subjects with hypogonadotropic hypogonadism [HH]).The main purpose of Study MBGS206 is to
evaluate long term safety and efficacy parameters in subjects after 12 months exposure with
BGS649.